Media stories about Kamada (NASDAQ:KMDA) have trended positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.5450874549158 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Kamada (KMDA) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- Zacks: Analysts Expect Kamada Ltd (KMDA) to Announce $0.03 Earnings Per Share (americanbankingnews.com)
- Kamada (KMDA) Upgraded at ValuEngine (americanbankingnews.com)
- Kamada (KMDA) Cut to Sell at ValuEngine (americanbankingnews.com)
- Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million (americanbankingnews.com)
KMDA stock traded up $0.10 during trading hours on Wednesday, hitting $5.00. The company had a trading volume of 6,820 shares, compared to its average volume of 22,144. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.30 and a quick ratio of 2.58. Kamada has a fifty-two week low of $3.75 and a fifty-two week high of $8.61. The firm has a market cap of $197.29, a price-to-earnings ratio of 29.41 and a beta of 1.12.
KMDA has been the subject of a number of recent analyst reports. ValuEngine lowered Kamada from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. Chardan Capital initiated coverage on Kamada in a research report on Friday, February 2nd. They issued a “buy” rating and a $7.00 price target for the company. HC Wainwright reiterated a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Finally, TheStreet upgraded Kamada from a “c” rating to a “b” rating in a research report on Friday, February 9th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.00.
TRADEMARK VIOLATION WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact Kamada (KMDA) Share Price” was first reported by BBNS and is the property of of BBNS. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://baseballnewssource.com/2018/03/21/kamada-kmda-earning-favorable-news-coverage-accern-reports/1924883.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.